Transcatheter aortic valve replacement (TAVR) is traditionally indicated for calcific aortic stenosis. Rheumatic aortic valve disease is treated surgically due to the younger age of patients and a lack of significant calcification that can anchor transcatheter valves. However, severe comorbidities may increase surgical risk, necessitating less invasive therapeutic modalities. Here, we present the first case report of severe rheumatic aortic stenosis with prior mechanical mitral valve prosthesis and liver cirrhosis that was successfully treated by TAVR.
Introduction
Transcatheter aortic valve replacement (TAVR) has become the procedure of choice for treating inoperable and high surgical risk patients with calcific degenerative severe symptomatic aortic stenosis [1, 2, 3, 4, 5, 6] . However, the utilization of TAVR for severe aortic stenosis caused by rheumatic valve disease is uncertain due to the lack of significant calcification necessary to anchor transcatheter valves. Here, we report a case of severe rheumatic aortic stenosis with prior mechanical mitral valve prosthesis and high surgical risk related to liver cirrhosis that was treated successfully with TAVR.
Case Presentation
A 62-year-old woman with rheumatic heart disease and chronic atrial fibrillation underwent mitral valve replacement using a mechanical valve prosthesis in 1991. The surgery was complicated by hepatitis C resulting from the recent development of liver cirrhosis. The patient presented with progressive dyspnea, orthopnea, and severe fluid overload consistent with class IV congestive heart failure. Diagnostic evaluation revealed severe aortic stenosis and tricuspid valve regurgitation, and she was referred for surgical aortic valve replacement and tricuspid valve repair. Hepatology evaluation suggested very high surgical risk due to chronic liver disease. Thus, she was referred for TAVR in the face of high surgical risk [7, 8] .
Echocardiography revealed a D-shape septum with a left ventricular ejection fraction of 50%, dilated left atrium and huge right atrium, and mildly dilated right ventricle with hypertrophy and normal systolic function. The aortic valve was fibrotic without significant calcification (consistent with rheumatic disease) with severe aortic stenosis and mild to moderate aortic regurgitation (annulus 20 mm, peak gradient 65 mmHg, mean gradient 42 mmHg, and calculated aortic valve area = 0.8 cm severe regurgitation with calculated pulmonary artery systolic pressure of 100 mmHg. Severe pulmonary hypertension appeared to be related to both prior mitral valve disorder and a recent development of congestive heart failure related to severe aortic stenosis.
Computerized tomographic angiography (CTA) showed the following: fibrotic aortic valve without significant calcification ( Figure 1A ), annular area = 365 mm 2 ( Figure 1B) , coronary sinus diameter = 26.5 mm and left main coronary height =12.9 mm ( Figure 1C ), right coronary height = 12.1 mm, and distance between the aortic annulus and mitral prosthetic valve = 10 mm ( Figure 1D ).
The procedure was performed in the catheterization laboratory under general anesthesia and transesophageal echocardiography (TEE) guidance. Percutaneous access was performed through the left common femoral artery with two ProGlide closure devices (Abbott Vascular Inc., Redwood City, California) pre-deployed to achieve homeostasis. Aortic valvuloplasty was performed using a 20-mm diameter balloon during rapid pacing, which showed full expansion and stability without displacement related to prior mitral valve prosthesis. Next, a 23-mm valve (Edwards Sapien XT, Edwards Lifesciences, Irvine, California) was introduced through the e-sheath and positioned across the aortic valve (Video 1). The valve was implanted using the rapid pacing technique and balloon inflation (Video 2). Post-procedural angiography revealed a well-positioned prosthesis without significant aortic regurgitation (Video 3), and TEE revealed a wellfunctioning aortic valve. A 23-mm valve provided 14% annular area oversizing, which was adequate to anchor and stabilize the valve in the absence of significant calcification. The patient was ambulated six hours after the procedure and discharged from the hospital three days later. At follow-up evaluation two weeks later, the patient showed a lack of symptoms, a well-functioning aortic valve, and improved pulmonary hypertension to 70 mmHg. The patient remained asymptomatic and stable 15 months after the procedure.
Discussion
To our knowledge, this is the first reported case of TAVR for rheumatic aortic stenosis with prior mechanical mitral valve prosthesis. This case has many unique features. In particular, rheumatic aortic valve disease usually lacks significant calcifications that are necessary to anchor the implanted valve and prevent its embolization. Also, the presence of prior mechanical mitral valve prosthesis could potentially complicate TAVR implantation by causing displacement, malposition, or even embolization. There are several usual recommendations for implanting a balloon-expandable transcatheter heart valve in patients with prior mitral valve prosthesis. First, the valve should be positioned more ventricularly due to anticipated aortic shift during deployment to prevent embolization. Second, stepwise and slow inflation of the valve is advised for proper and controlled implantation. Third, the implantation should be guided by aortography and TEE to evaluate interaction with the mitral prosthesis. We also believe that balloon valvuloplasty is mandatory in such cases prior to valve implantation for Alhaddad, I.A.
TAVR for Rheumatic Aortic Stenosis the following reasons. First, an inflated balloon can confirm full expansion of the fibrotic aortic valve leaflets. Second, balloon stability during inflation can indicate good anchoring, suggesting that the implanted valve is less likely to embolize. Third, it can allow examination of the interaction between the aortic valve and mitral prosthesis that could potentially cause displacement or malposition. Rheumatic valve disease usually inflicts younger patients, and surgical valve replacement is the procedure of choice for these patients. However, the presence of comorbidities (i.e., liver cirrhosis) and prior mitral valve prosthesis makes TAVR a potentially excellent solution for severe aortic stenosis.
Review of the literature revealed several case reports of TAVR in rheumatic heart disease. Bilge et al. described two patients with rheumatic aortic stenosis and high surgical risk who ultimately underwent TAVR [9] . Akujuo et al. presented a case in which TAVR was combined with transcatheter mitral valve implantation in a patient with both aortic and mitral valves affected by rheumatic valve stenosis [10] . Chainani et al. reported a case of left main percutaneous coronary intervention and TAVR in a patient with rheumatic heart disease and porcelain aorta mitral valve prosthesis in the presence of high-risk features for surgical valve replacement. A registry of such patients with longer-term follow-up is necessary to establish the role of TAVR in rheumatic aortic stenosis.
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In conclusion, the indications for TAVR are evolving to include a wider range of patients and different valvular disorders. This is the first case demonstrating the feasibility of TAVR for rheumatic aortic stenosis with prior
